rewirebio.iobenchmarks
Configuration

GPT-5 2025-08-07 with CIViC MCP, March 2026

OpenAI Agents SDK + FastMCP; new subprocess/query, auto tool selection, default 10 model/tool cycles.

1 evaluation · 54 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Model Capabilities & Hardware Requirements

Deployment facts recorded for GPT-5 2025-08-07 with CIViC MCP, March 2026. Fields the record does not carry are marked not recorded.

ParametersNot recorded
Minimum VRAMNot recorded
Inference LatencyNot recorded
Context WindowNot recorded
AccessNot recorded
LicenseNot recorded

Evaluations and results

1 evaluation · 54 results. Different protocols are not a single leaderboard.

Protocol: CIViC evidence-direction retrieval, March 2026 · Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026

Sorted by Accuracy (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configurationAccuracyF1 (class: diagnostic negative)F1 (class: diagnostic positive)F1 (class: functional dominant negative)F1 (class: functional gain of function)F1 (class: functional loss of function)F1 (class: functional unaltered function)F1 (class: oncogenic oncogenicity)F1 (class: predictive reduced sensitivity)F1 (class: predictive resistance)F1 (class: predictive sensitivity)F1 (class: predisposing n/a)F1 (class: predisposing predisposition)F1 (class: predisposing uncertain significance)F1 (class: prognostic better outcome)F1 (class: prognostic poor outcome)Micro F1Micro F1 (evidence type: diagnostic)Micro F1 (evidence type: functional)Micro F1 (evidence type: oncogenic)Micro F1 (evidence type: predictive)Micro F1 (evidence type: predisposing)Micro F1 (evidence type: prognostic)Precision (class: diagnostic negative)Precision (class: diagnostic positive)Precision (class: functional dominant negative)Precision (class: functional gain of function)Precision (class: functional loss of function)Precision (class: functional unaltered function)Precision (class: oncogenic oncogenicity)Precision (class: predictive reduced sensitivity)Precision (class: predictive resistance)Precision (class: predictive sensitivity)Precision (class: predisposing n/a)Precision (class: predisposing predisposition)Precision (class: predisposing uncertain significance)Precision (class: prognostic better outcome)Precision (class: prognostic poor outcome)Recall (class: diagnostic negative)Recall (class: diagnostic positive)Recall (class: functional dominant negative)Recall (class: functional gain of function)Recall (class: functional loss of function)Recall (class: functional unaltered function)Recall (class: oncogenic oncogenicity)Recall (class: predictive reduced sensitivity)Recall (class: predictive resistance)Recall (class: predictive sensitivity)Recall (class: predisposing n/a)Recall (class: predisposing predisposition)Recall (class: predisposing uncertain significance)Recall (class: prognostic better outcome)Recall (class: prognostic poor outcome)Runtime (mean per query)
GPT-5 2025-08-07 with CIViC MCP, March 2026Evaluation0.950.66111110.9610.970.980.9410.92110.980.95110.980.9611111111111111110.5111110.9210.940.960.8910.861143.1
All 54 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
0.95 Accuracy
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Fig1c Overall Accuracy; Section 3
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
0.95 Micro F1 (evidence type: diagnostic)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Figure 1c, diagnostic row, mcp column
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
0.66 F1 (class: diagnostic negative)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Diagnostic / Negative, f1
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Precision (class: diagnostic negative)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Diagnostic / Negative, precision
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
0.5 Recall (class: diagnostic negative)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Diagnostic / Negative, recall
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 F1 (class: diagnostic positive)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Diagnostic / Positive, f1
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Precision (class: diagnostic positive)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Diagnostic / Positive, precision
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Recall (class: diagnostic positive)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Diagnostic / Positive, recall
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 F1 (class: functional dominant negative)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Dominant Negative, f1
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Precision (class: functional dominant negative)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Dominant Negative, precision
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Recall (class: functional dominant negative)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Dominant Negative, recall
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Micro F1 (evidence type: functional)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Figure 1c, functional row, mcp column
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 F1 (class: functional gain of function)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Gain of Function, f1
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Precision (class: functional gain of function)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Gain of Function, precision
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Recall (class: functional gain of function)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Gain of Function, recall
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 F1 (class: functional loss of function)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Loss of Function, f1
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Precision (class: functional loss of function)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Loss of Function, precision
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Recall (class: functional loss of function)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Loss of Function, recall
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 F1 (class: functional unaltered function)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Unaltered Function, f1
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Precision (class: functional unaltered function)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Unaltered Function, precision
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Recall (class: functional unaltered function)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Functional / Unaltered Function, recall
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
0.98 Micro F1
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Fig1c Micro F1; Section 3
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Micro F1 (evidence type: oncogenic)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP: integrating large language models with the Clinical Interpretations of Variants in Cancer · Figure 1c, oncogenic row, mcp column
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
0.96 F1 (class: oncogenic oncogenicity)
unitless · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Oncogenic / Oncogenicity, f1
Configuration: GPT-5 2025-08-07 with CIViC MCP, March 2026Protocol: CIViC evidence-direction retrieval, March 2026
Dataset: CIViC 100 molecular-profile/disease/therapy triplets, March 2026
1 Precision (class: oncogenic oncogenicity)
fraction · higher

Uncertainty: Not reported by the source: not reported for this endpoint

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

CIViC mcp retrieval

Not reported

Aggregation: Not reported

CIViC MCP supplementary methods and complete Tables 1–3 · Supplementary Table 1, Oncogenic / Oncogenicity, precision

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Use this configuration

How it works, versions and access

Related profile: CIViC fixed-schema evidence retrieval evaluation workflow. This page retains the exact record and its evaluation context.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

2 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Facets: method types
1 values
  • foundation_model
Individual claims
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

Record names and descriptions: GPT-5, ChatGPT Agent Mode and Qwen3-Reranker-8B are large pretrained language models used without task training

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

conflicting claim

["automated-source-review"] · 2026-10-12

Audit details

Correct the method type from none to foundation_model (use-case baseline review 2026-10-12, table 2). The review marks these as the proposer's, not source-checked. Evidence from docs/reviews/use-cases/baselines-2026-10-12.md. Independent review 2026-10-12: approved. See docs/reviews/2026-10-12-method-type-corrections.md.

Conflicting source claim: "[\"foundation_model\"]". Claim record status: source_checked.

Field: facets.method_types

Claim: metadata-correction-tags-20261012-a0d59d380aeed3c3be73

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Relationship: configuration of
uc-clinical-20260930-pipeline-civic-retrieval
Individual claims
CIViC MCP supplementary methods and complete Tables 1–3

Original source ↗

Supplementary implementation and Agent Mode evaluation methods

Version: vbag209_supplementary_data.docx, final article supplement
Retrieved: 2026-09-30T21:25:48Z

source checked

["automated-source-review"] · 2026-09-30

Audit details

Transcription from inspected primary source. No execution, independent replication or human scientific review.

Field: links:configuration_of:uc-clinical-20260930-pipeline-civic-retrieval

Claim: uc-clinical-20260930-association-civic-gpt5-mcp

Source artifact SHA-256: 857b272f9f29b9cb35d4fba7f424ef31d664d8acf8a23475c7c626a452b2e9e6

Hash scope: Hash scope not separately documented; inspect source record

Inspected artifact

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID uc-clinical-20260930-civic-gpt5-mcp.

Related records

How to cite

GPT-5 2025-08-07 with CIViC MCP, March 2026. Rewire biological model benchmark database, release 2026-11-21-c8bea25e5abb. https://benchmarks.rewirebio.io/database/configuration/uc-clinical-20260930-civic-gpt5-mcp/

Release 2026-11-21-c8bea25e5abb. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.

The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence

Suggest a correction